339 related articles for article (PubMed ID: 31587152)
21. HER2 activating mutations are targets for colorectal cancer treatment.
Kavuri SM; Jain N; Galimi F; Cottino F; Leto SM; Migliardi G; Searleman AC; Shen W; Monsey J; Trusolino L; Jacobs SA; Bertotti A; Bose R
Cancer Discov; 2015 Aug; 5(8):832-41. PubMed ID: 26243863
[TBL] [Abstract][Full Text] [Related]
22. Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.
Lo Nigro C; Ricci V; Vivenza D; Granetto C; Fabozzi T; Miraglio E; Merlano MC
World J Gastroenterol; 2016 Aug; 22(30):6944-54. PubMed ID: 27570430
[TBL] [Abstract][Full Text] [Related]
23. Dynamic monitoring of HER2 amplification in circulating DNA of patients with metastatic colorectal cancer treated with cetuximab.
Liu R; Zhao X; Guo W; Huang M; Qiu L; Zhang W; Zhang Z; Li W; Zhu X; Chen Z
Clin Transl Oncol; 2020 Jun; 22(6):928-934. PubMed ID: 31571151
[TBL] [Abstract][Full Text] [Related]
24. HER2
Gharib E; Salmanipour R; Nazemalhosseini Mojarad E; Yaghoob Taleghani M; Sarlak S; Malekzade-Moghani M; Nasrabadi PN; Meiary MA; Asadzadeh Aghdaei H; Zali MR
J Cell Physiol; 2019 Aug; 234(8):13137-13144. PubMed ID: 30549033
[TBL] [Abstract][Full Text] [Related]
25. RAS-expanded Mutations and HER2 Expression in Metastatic Colorectal Cancer: A New Step of Precision Medicine.
Valentini AM; Cavalcanti E; Di Maggio M; Caruso ML
Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):539-544. PubMed ID: 30199395
[TBL] [Abstract][Full Text] [Related]
26. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
27. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
[TBL] [Abstract][Full Text] [Related]
28. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
[TBL] [Abstract][Full Text] [Related]
29. Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer.
Guarini C; Grassi T; Pezzicoli G; Porta C
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34202896
[TBL] [Abstract][Full Text] [Related]
30. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.
Kasper S; Reis H; Ziegler S; Nothdurft S; Mueller A; Goetz M; Wiesweg M; Phasue J; Ting S; Wieczorek S; Even A; Worm K; Pogorzelski M; Breitenbuecher S; Meiler J; Paul A; Trarbach T; Schmid KW; Breitenbuecher F; Schuler M
Oncotarget; 2017 Jul; 8(28):45898-45917. PubMed ID: 28507280
[TBL] [Abstract][Full Text] [Related]
31. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.
Zhou J; Ji Q; Li Q
J Exp Clin Cancer Res; 2021 Oct; 40(1):328. PubMed ID: 34663410
[TBL] [Abstract][Full Text] [Related]
32. Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies.
Mizukami T; Togashi Y; Naruki S; Banno E; Terashima M; de Velasco MA; Sakai K; Yoneshige A; Hayashi H; Fujita Y; Tomida S; Nakajima TE; Fujino T; Boku N; Ito A; Nakagawa K; Nishio K
Mol Carcinog; 2017 Jan; 56(1):106-117. PubMed ID: 26916220
[TBL] [Abstract][Full Text] [Related]
33. Targeted therapy for metastatic colorectal cancer.
Price TJ; Tang M; Gibbs P; Haller DG; Peeters M; Arnold D; Segelov E; Roy A; Tebbutt N; Pavlakis N; Karapetis C; Burge M; Shapiro J
Expert Rev Anticancer Ther; 2018 Oct; 18(10):991-1006. PubMed ID: 30019590
[TBL] [Abstract][Full Text] [Related]
34. HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF.
Jeong JH; Kim J; Hong YS; Kim D; Kim JE; Kim SY; Kim KP; Yoon YK; Kim D; Chun SM; Park Y; Jang SJ; Kim TW
Clin Colorectal Cancer; 2017 Sep; 16(3):e147-e152. PubMed ID: 28223103
[TBL] [Abstract][Full Text] [Related]
35. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
Ross JS; Fakih M; Ali SM; Elvin JA; Schrock AB; Suh J; Vergilio JA; Ramkissoon S; Severson E; Daniel S; Fabrizio D; Frampton G; Sun J; Miller VA; Stephens PJ; Gay LM
Cancer; 2018 Apr; 124(7):1358-1373. PubMed ID: 29338072
[TBL] [Abstract][Full Text] [Related]
36. KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.
Li W; Shi Q; Wang W; Liu J; Ren J; Li Q; Hou F
Colorectal Dis; 2014 Nov; 16(11):O370-8. PubMed ID: 25155261
[TBL] [Abstract][Full Text] [Related]
37. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.
Siena S; Sartore-Bianchi A; Marsoni S; Hurwitz HI; McCall SJ; Penault-Llorca F; Srock S; Bardelli A; Trusolino L
Ann Oncol; 2018 May; 29(5):1108-1119. PubMed ID: 29659677
[TBL] [Abstract][Full Text] [Related]
38. Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results.
Mohamed A; Twardy B; AbdAllah N; Akhras A; Ismail H; Zordok M; Schrapp K; Attumi T; Tesfaye A; El-Rayes B
J Gastrointest Cancer; 2019 Jun; 50(2):269-275. PubMed ID: 29388061
[TBL] [Abstract][Full Text] [Related]
39. Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapies.
Barton S; Starling N; Swanton C
Curr Cancer Drug Targets; 2010 Dec; 10(8):799-812. PubMed ID: 20718710
[TBL] [Abstract][Full Text] [Related]
40. Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models.
Vangala D; Ladigan S; Liffers ST; Noseir S; Maghnouj A; Götze TM; Verdoodt B; Klein-Scory S; Godfrey L; Zowada MK; Huerta M; Edelstein DL; de Villarreal JM; Marqués M; Kumbrink J; Jung A; Schiergens T; Werner J; Heinemann V; Stintzing S; Lindoerfer D; Mansmann U; Pohl M; Teschendorf C; Bernhardt C; Wolters H; Stern J; Usta S; Viebahn R; Admard J; Casadei N; Fröhling S; Ball CR; Siveke JT; Glimm H; Tannapfel A; Schmiegel W; Hahn SA
Genome Med; 2021 Jul; 13(1):116. PubMed ID: 34271981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
